Menveo is a vaccine for individuals 2 months through 55 years of age. It helps prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
According to the prescribing information, MENVEO is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age.
Key Points:
- Age Range: 2 months to 55 years.
- Protection: Protects against Neisseria meningitidis serogroups A, C, Y, and W-135.
- Limitation: Does not protect against serogroup B infections.
In summary, MENVEO is suitable for a broad age range, from infants as young as 2 months old to adults up to 55 years old, to provide protection against specific types of meningococcal disease.
